HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.
Hemogenyx Pharmaceuticals announced that its total issued share capital as of March 31, 2025, consists of 4,093,539 ordinary shares, with no shares held in treasury. This figure is crucial for shareholders to calculate their investment notifications under the Financial Conduct Authority’s rules, impacting how they manage their interests in the company’s share capital.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new therapies and treatments for blood and autoimmune diseases, utilizing distinct and complementary product candidates and platform technologies.
YTD Price Performance: -52.16%
Average Trading Volume: 32,684
Technical Sentiment Signal: Buy
Current Market Cap: £7.93M
Learn more about HEMO stock on TipRanks’ Stock Analysis page.